Matthieu Peyre1, Danielle Miyagishima1, Franck Bielle1, Françoise Chapon1, Michael Sierant1, Quitterie Venot1, Julie Lerond1, Pauline Marijon1, Samiya Abi-Jaoude1, Tuan Le Van1, Karim Labreche1, Richard Houlston1, Maxime Faisant1, Stéphane Clémenceau1, Anne-Laure Boch1, Aurelien Nouet1, Alexandre Carpentier1, Julien Boetto1, Angeliki Louvi1, Michel Kalamarides1. 1. From the Departments of Neurosurgery (M.P., S.C., A.-L.B., A.N., A.C., M.K.) and Neuropathology (F.B.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, INSERM Unité 1127, Centre National de la Recherche Scientifique Unité Mixte de Recherche 7225, Paris Brain Institute (M.P., F.B., J.L., P.M., S.A.-J., T.L.V., K.L., J.B., M.K.), and INSERM Unité 1151-Institut Necker Enfants Malades, Hôpital Necker Enfants Malades, AP-HP (Q.V.), Paris, and the Department of Pathology, Centre Hospitalier Régional Universitaire (CHRU) Caen-INSERM Unité 1075 COMETE, Caen University (F.C.), and the Department of Pathology CHRU Caen-INSERM Unité Mixte de Recherche en Santé Unité 1237, Cyceron (M.F.), Caen - all in France; the Departments of Genetics (D.M., M.S.) and Neurosurgery and Neuroscience (A.L.), Yale School of Medicine, New Haven, CT; and the Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, United Kingdom (K.L., R.H.).
Abstract
BACKGROUND: Cerebral cavernous malformations (CCMs) are common sporadic and inherited vascular malformations of the central nervous system. Although familial CCMs are linked to loss-of-function mutations in KRIT1 (CCM1), CCM2, or PDCD10 (CCM3), the genetic cause of sporadic CCMs, representing 80% of cases, remains incompletely understood. METHODS: We developed two mouse models harboring mutations identified in human meningiomas with the use of the prostaglandin D2 synthase (PGDS) promoter. We performed targeted DNA sequencing of surgically resected CCMs from patients and confirmed our findings by droplet digital polymerase-chain-reaction analysis. RESULTS: We found that in mice expressing one of two common genetic drivers of meningioma - Pik3ca H1047R or AKT1 E17K - in PGDS-positive cells, a spectrum of typical CCMs develops (in 22% and 11% of the mice, respectively) instead of meningiomas, which prompted us to analyze tissue samples from sporadic CCMs from 88 patients. We detected somatic activating PIK3CA and AKT1 mutations in 39% and 1%, respectively, of lesion tissue from the patients. Only 10% of lesions harbored mutations in the CCM genes. We analyzed lesions induced by the activating mutations Pik3ca H1074R and AKT1 E17K in mice and identified the PGDS-expressing pericyte as the probable cell of origin. CONCLUSIONS: In tissue samples from sporadic CCMs, mutations in PIK3CA were represented to a greater extent than mutations in any other gene. The contribution of somatic mutations in the genes that cause familial CCMs was comparatively small. (Funded by the Fondation ARC pour la Recherche contre le Cancer and others.).
BACKGROUND: Cerebral cavernous malformations (CCMs) are common sporadic and inherited vascular malformations of the central nervous system. Although familial CCMs are linked to loss-of-function mutations in KRIT1 (CCM1), CCM2, or PDCD10 (CCM3), the genetic cause of sporadic CCMs, representing 80% of cases, remains incompletely understood. METHODS: We developed two mouse models harboring mutations identified in human meningiomas with the use of the prostaglandin D2 synthase (PGDS) promoter. We performed targeted DNA sequencing of surgically resected CCMs from patients and confirmed our findings by droplet digital polymerase-chain-reaction analysis. RESULTS: We found that in mice expressing one of two common genetic drivers of meningioma - Pik3ca H1047R or AKT1 E17K - in PGDS-positive cells, a spectrum of typical CCMs develops (in 22% and 11% of the mice, respectively) instead of meningiomas, which prompted us to analyze tissue samples from sporadic CCMs from 88 patients. We detected somatic activating PIK3CA and AKT1 mutations in 39% and 1%, respectively, of lesion tissue from the patients. Only 10% of lesions harbored mutations in the CCM genes. We analyzed lesions induced by the activating mutations Pik3ca H1074R and AKT1 E17K in mice and identified the PGDS-expressing pericyte as the probable cell of origin. CONCLUSIONS: In tissue samples from sporadic CCMs, mutations in PIK3CA were represented to a greater extent than mutations in any other gene. The contribution of somatic mutations in the genes that cause familial CCMs was comparatively small. (Funded by the Fondation ARC pour la Recherche contre le Cancer and others.).
Authors: Javier A Couto; August Y Huang; Dennis J Konczyk; Jeremy A Goss; Steven J Fishman; John B Mulliken; Matthew L Warman; Arin K Greene Journal: Am J Hum Genet Date: 2017-02-09 Impact factor: 11.025
Authors: Riccardo Cassiani-Ingoni; Turhan Coksaygan; Haipeng Xue; Susan A Reichert-Scrivner; Heinz Wiendl; Mahendra S Rao; Tim Magnus Journal: Exp Neurol Date: 2006-06-30 Impact factor: 5.330
Authors: María D Ganfornina; Diego Sánchez; Aldo Pagano; Laura Tonachini; Fiorella Descalzi-Cancedda; Salvador Martínez Journal: Dev Dyn Date: 2005-01 Impact factor: 3.780
Authors: Victoria E Clark; Akdes Serin Harmancı; Hanwen Bai; Mark W Youngblood; Tong Ihn Lee; Jacob F Baranoski; A Gulhan Ercan-Sencicek; Brian J Abraham; Abraham S Weintraub; Denes Hnisz; Matthias Simon; Boris Krischek; E Zeynep Erson-Omay; Octavian Henegariu; Geneive Carrión-Grant; Ketu Mishra-Gorur; Daniel Durán; Johanna E Goldmann; Johannes Schramm; Roland Goldbrunner; Joseph M Piepmeier; Alexander O Vortmeyer; Jennifer Moliterno Günel; Kaya Bilgüvar; Katsuhito Yasuno; Richard A Young; Murat Günel Journal: Nat Genet Date: 2016-08-22 Impact factor: 38.330
Authors: Ana Filipa Geraldo; Cesar Augusto P F Alves; Aysha Luis; Domenico Tortora; Joana Guimarães; Daisy Abreu; Sofia Reimão; Marco Pavanello; Patrizia de Marco; Marcello Scala; Valeria Capra; Rui Vaz; Andrea Rossi; Erin Simon Schwartz; Kshitij Mankad; Mariasavina Severino Journal: Neuroradiology Date: 2022-10-06 Impact factor: 2.995
Authors: Matthew J Hagan; Robert Shenkar; Abhinav Srinath; Sharbel G Romanos; Agnieszka Stadnik; Mark L Kahn; Douglas A Marchuk; Romuald Girard; Issam A Awad Journal: ACS Pharmacol Transl Sci Date: 2022-04-25
Authors: Piotr Kobialka; Helena Sabata; Sandra D Castillo; Mariona Graupera; Odena Vilalta; Leonor Gouveia; Ana Angulo-Urarte; Laia Muixí; Jasmina Zanoncello; Oscar Muñoz-Aznar; Nagore G Olaciregui; Lucia Fanlo; Anna Esteve-Codina; Cinzia Lavarino; Biola M Javierre; Veronica Celis; Carlota Rovira; Susana López-Fernández; Eulàlia Baselga; Jaume Mora Journal: EMBO Mol Med Date: 2022-06-13 Impact factor: 14.260
Authors: Anthony C Y Yau; Maria Ascencion Globisch; Favour Chinyere Onyeogaziri; Lei L Conze; Ross Smith; Suvi Jauhiainen; Monica Corada; Fabrizio Orsenigo; Hua Huang; Melanie Herre; Anna-Karin Olsson; Matteo Malinverno; Veronica Sundell; Behnam Rezai Jahromi; Mika Niemelä; Aki Laakso; Cecilia Garlanda; Alberto Mantovani; Maria Grazia Lampugnani; Elisabetta Dejana; Peetra U Magnusson Journal: Cell Mol Life Sci Date: 2022-03-25 Impact factor: 9.207